Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer’s Disease Drugs

Rajeev Shrestha; Hiroaki Saito; Erika Yamashita; Sunil Shrestha; Tetsuya Tanimoto; Akihiko Ozaki

doi:10.7759/cureus.53848

journal article Feb 08, 2024

Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer’s Disease Drugs

Rajeev Shrestha

Hiroaki Saito

Erika Yamashita

Sunil Shrestha Tetsuya Tanimoto Akihiko Ozaki

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.53848

Topics

No keywords indexed for this article. Browse by subject →

References

30

[1]

Mitchell AP, Trivedi NU, Gennarelli RL, et al.. Are financial payments from the pharmaceutical industry associated with physician prescribing?: a systematic review. Ann Intern Med. 2021, 174:353-61. 10.7326/M20-5665 10.7326/m20-5665

[2]

Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017, 2:MR000033. 10.1002/14651858.MR000033.pub3 10.1002/14651858.mr000033.pub3

[3]

Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and distribution of payments from industry to physicians in 2015. JAMA. 2017, 317:1774-84. 10.1001/jama.2017.3091 10.1001/jama.2017.3091

[4]

Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of industry payments to physicians: an epidemiologic analysis of early data from the Open Payments Program. Mayo Clin Proc. 2016, 91:84-96. 10.1016/j.mayocp.2015.10.016 10.1016/j.mayocp.2015.10.016

[5]

Ozaki A, Saito H, Senoo Y, et al.. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016. Health Policy. 2020, 124:727-35. 10.1016/j.healthpol.2020.03.011 10.1016/j.healthpol.2020.03.011

[6]

Murayama A, Hoshi M, Saito H, et al.. Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019. Respiration. 2022, 101:1088-98. 10.1159/000526576 10.1159/000526576

[7]

Lexchin J. Health services and policy research in Canada: an editor’s reflections. Healthc Policy. 2022, 17:42-8. 10.12927/hcpol.2022.26729 10.12927/hcpol.2022.26729

[8]

Chambliss WG, Carroll WA, Kennedy D, et al.. Role of the pharmacist in preventing distribution of counterfeit medications. J Am Pharm Assoc (2003). 2012, 52:195-9. 10.1331/JAPhA.2012.11085 10.1331/japha.2012.11085

[9]

Singh A, Hyman MJ, Modi PK. Evaluation of industry payments to US advanced practice clinicians in 2021. JAMA Netw Open. 2022, 5:e2242869. 10.1001/jamanetworkopen.2022.42869 10.1001/jamanetworkopen.2022.42869

[10]

Nalleballe K, Sheng S, Li C, et al.. Industry payment to vascular neurologists: a 6-year analysis of the Open Payments Program from 2013 through 2018. Stroke. 2020, 51:1339-43. 10.1161/STROKEAHA.119.027967 10.1161/strokeaha.119.027967

[11]

Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: the 2015 Open Payments database. Neurology. 2019, 92:1006-13. 10.1212/WNL.0000000000007640 10.1212/wnl.0000000000007640

[12]

Statistics Bureau, Ministry of Internal Affairs and Communications. (2023). Accessed. January 22, 2024: https://www.stat.go.jp/data/topics/topi1321.html.

[13]

Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, Tomita K. Economic burden of Alzheimer's disease dementia in Japan. J Alzheimers Dis. 2021, 81:309-19. 10.3233/JAD-210075 10.3233/jad-210075

[14]

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al.

New England Journal of Medicine 2023 10.1056/nejmoa2212948

[15]

Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep. 2023, 13:7425. 10.1038/s41598-023-34705-8 10.1038/s41598-023-34705-8

[16]

Kamamoto S, Murayama A, Kusumi E, et al.. Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019. Pediatr Blood Cancer. 2022, 69:e29891. 10.1002/pbc.29891 10.1002/pbc.29891

[17]

Kusumi E, Murayama A, Kamamoto S, et al.. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J. 2022, 12:54. 10.1038/s41408-022-00656-y 10.1038/s41408-022-00656-y

[18]

Murayama A, Hoshi M, Saito H, et al.. Nature and trends of pharmaceutical payments to the board certified respiratory specialists in Japan between 2016 and 2019 [PREPRINT]. medRxiv. 2022, 10.1101/2022.01.16.22269188 10.1101/2022.01.16.22269188

[19]

Murayama A, Shigeta H, Kamamoto S, et al.. Pharmaceutical payments to Japanese board-certified head and neck surgeons between 2016 and 2019. OTO Open. 2023, 7:e31. 10.1002/oto2.31 10.1002/oto2.31

[20]

Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open. 2023, 13:e068237. 10.1136/bmjopen-2022-068237 10.1136/bmjopen-2022-068237

[21]

Nalleballe K, Veerapaneni KD, Harada Y, et al.. Trends of industry payments in neurology subspecialties. Cureus. 2020, 12:e9492. 10.7759/cureus.9492 10.7759/cureus.9492

[22]

Program overview. (2022). Accessed. January 11, 2024: https://openpaymentsdata.cms.gov/about.

[23]

Ozaki A, Saito H, Onoue Y, et al.. Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. BMJ Open. 2019, 9:e028805. 10.1136/bmjopen-2018-028805 10.1136/bmjopen-2018-028805

[24]

Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts

James S. Yeh, Jessica M. Franklin, Jerry Avorn et al.

JAMA Internal Medicine 2016 10.1001/jamainternmed.2016.1709

[25]

Mitchell AP, Winn AN, Lund JL, Dusetzina SB. Evaluating the strength of the association between industry payments and prescribing practices in oncology. Oncologist. 2019, 24:632-9. 10.1634/theoncologist.2018-0423 10.1634/theoncologist.2018-0423

[26]

Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: the 2015 Open Payments database. Neurology. 2018, 90:1063-70. 10.1212/WNL.0000000000005657 10.1212/wnl.0000000000005657

[27]

Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract. 2023, 29:883-6. 10.1111/jep.13877 10.1111/jep.13877

[28]

Murayama A, Kamamoto S, Murata N, et al.. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023, 38:565-73. 10.1111/jgh.16089 10.1111/jgh.16089

[29]

Double haul of Japanese approvals for Eisai. (2020). Accessed. January 11, 2024: https://www.thepharmaletter.com/article/double-haul-of-japanese-approvals-for-eisai..

[30]

Launch of aspirin/vonoprazan fumarate combination tablets. ‘Cabpirin® combination tablets’. (2020). Accessed: January 12, 2024: https://www.otsuka.co.jp/en/company/newsreleases/2020/20200522_1.html.

Metrics

1

Citations

30

References

Details

Published: Feb 08, 2024

Authors

Department of Gastroenterology, Sendai Kousei Hospital, Miyagi, Japan

Cite This Article

Rajeev Shrestha, Hiroaki Saito, Erika Yamashita, et al. (2024). Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer’s Disease Drugs. Cureus. https://doi.org/10.7759/cureus.53848

Nature and Trend of Pharmaceutical Payments to Japanese Board-Certified Neurologists Between 2016 and 2019: A Pre-emergence Analysis Amidst the Development of Next-Generation Alzheimer’s Disease Drugs

You May Also Like